Jump to content

EICAR (antiviral)

Edit links
From Wikipedia, the free encyclopedia
Not to be confused with AICA ribonucleotide.

EICAR
Clinical data
Other names5-Ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide
Legal status
Legal status
Identifiers
  • 1-[(3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H13N3O5
Molar mass267.241 g·mol−1
3D model (JSmol)
  • NC(=O)c1ncn(c1C#C)C2[C@H](O)[C@H](O)[C@H](O2)CO
  • InChI=1S/C11H13N3O5/c1-2-5-7(10(12)18)13-4-14(5)11-9(17)8(16)6(3-15)19-11/h1,4,6,8-9,11,15-17H,3H2,(H2,12,18)/t6-,8-,9-,11?/m1/s1
  • Key:SWQQELWGJDXCFT-ABHRNEANSA-N

EICAR (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide) is a nucleoside analogue which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia,[1][2] but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against pox viruses, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others,[3][4][5] although it is not active against coronaviridae such as SARS-CoV-1.[6] This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases.[7][8][9]

EICAR was originally discovered as a potent inhibitor of the human enzyme IMP dehydrogenase, part of the guanylate biosynthesis pathway.[10][11] This activity is responsible for its known anticancer[10] and antiviral[12][13] effects.

References

[edit]
  1. ^ Matsuda A, Minakawa N, Sasaki T, Ueda T (July 1988). "The design, synthesis and antileukemic activity of 5-alkynyl-1-beta-D-ribofuranosylimidazole-4-carboxamides". Chemical & Pharmaceutical Bulletin. 36 (7): 2730–2733. doi:10.1248/cpb.36.2730. PMID 3272143.
  2. ^ Minakawa N, Takeda T, Sasaki T, Matsuda A, Ueda T (February 1991). "Nucleosides and nucleotides. 96. Synthesis and antitumor activity of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives". Journal of Medicinal Chemistry. 34 (2): 778–786. doi:10.1021/jm00106a045. PMID 1995901.
  3. ^ De Clercq E, Cools M, Balzarini J, Snoeck R, Andrei G, Hosoya M, et al. (April 1991). "Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4- carboxamide and related compounds". Antimicrobial Agents and Chemotherapy. 35 (4): 679–684. doi:10.1128/aac.35.4.679. PMC 245078. PMID 2069373.
  4. ^ Jashés M, González M, López-Lastra M, De Clercq E, Sandino A (March 1996). "Inhibitors of infectious pancreatic necrosis virus (IPNV) replication". Antiviral Research. 29 (2–3): 309–312. doi:10.1016/0166-3542(96)80226-9. PMID 8739609.
  5. ^ Dal Pozzo F, Galligioni V, Vaccari F, Gallina L, Battilani M, Scagliarini A (April 2010). "Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro". Research in Veterinary Science. 88 (2): 339–344. doi:10.1016/j.rvsc.2009.08.010. PMID 19781726.
  6. ^ Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al. (August 2006). "Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin". Antiviral Research. 71 (1): 53–63. doi:10.1016/j.antiviral.2006.03.001. PMC 7114261. PMID 16621037.
  7. ^ De Clercq E (2015). "Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential". Current Medicinal Chemistry. 22 (34): 3866–3880. doi:10.2174/0929867322666150625094705. PMID 26112146.
  8. ^ Okano Y, Saito-Tarashima N, Kurosawa M, Iwabu A, Ota M, Watanabe T, et al. (June 2019). "Synthesis and biological evaluation of novel imidazole nucleosides as potential anti-dengue virus agents". Bioorganic & Medicinal Chemistry. 27 (11): 2181–2186. doi:10.1016/j.bmc.2019.04.015. PMID 31003866. S2CID 124129370.
  9. ^ De Clercq E (November 2019). "New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections". Chemistry: An Asian Journal. 14 (22): 3962–3968. doi:10.1002/asia.201900841. PMC 7159701. PMID 31389664.
  10. ^ a b Balzarini J, Karlsson A, Wang L, Bohman C, Horská K, Votruba I, et al. (November 1993). "Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis". The Journal of Biological Chemistry. 268 (33): 24591–24598. doi:10.1016/S0021-9258(19)74507-4. PMID 7901217.
  11. ^ Qian X, Liu H, Xu D, Xu L, Huang F, He W, et al. (September 2017). "Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis". The Aging Male. 20 (3): 184–191. doi:10.1080/13685538.2017.1295436. PMID 28368238. S2CID 25963580.
  12. ^ Jashés M, Mlynarz G, De Clercq E, Sandino AM (January 2000). "Inhibitory effects of EICAR on infectious pancreatic necrosis virus replication". Antiviral Research. 45 (1): 9–17. doi:10.1016/S0166-3542(99)00071-6. PMID 10774586.
  13. ^ Dal Pozzo F, Galligioni V, Vaccari F, Gallina L, Battilani M, Scagliarini A (April 2010). "Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro". Research in Veterinary Science. 88 (2): 339–344. doi:10.1016/j.rvsc.2009.08.010. PMID 19781726.
Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EICAR_(antiviral)&oldid=1248785587"